- Business Wire•23 hours agoEnanta Pharmaceuticals Announces AbbVie’s Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation
Enanta Pharmaceuticals, Inc., , a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the U.S.
- PR Newswire•23 hours ago
NORTH CHICAGO, Ill., Sept. 30, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy ...
- Business Wire•2 days agoEnanta Pharmaceuticals Presents Data on a Novel Non-Fusion Inhibitor of Respiratory Syncytial Virus (RSV) at the 10th Annual Respiratory Syncytial Virus Conference
Enanta Pharmaceuticals, Inc., , a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that a poster presentation on one of the lead compounds in its RSV program was presented today at the 10th Annual Respiratory Syncytial Virus conference taking place September 28 through October 1, in Patagonia, ...
Enanta Pharmaceuticals, Inc. (ENTA)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||23.00 x 200|
|Day's Range||25.71 - 26.87|
|52wk Range||16.75 - 41.77|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||17.60|
|Avg Vol (3m)||272,528|
|Dividend & Yield||N/A (N/A)|